Compare ACCL & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACCL | CVM |
|---|---|---|
| Founded | 2009 | 1983 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.3M | 30.6M |
| IPO Year | 2024 | 1996 |
| Metric | ACCL | CVM |
|---|---|---|
| Price | $2.54 | $1.57 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $12.50 |
| AVG Volume (30 Days) | 5.6K | ★ 273.5K |
| Earning Date | 11-16-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $264,033.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $17.13 | ★ N/A |
| Revenue Growth | N/A | ★ 65.45 |
| 52 Week Low | $1.23 | $0.89 |
| 52 Week High | $5.00 | $9.28 |
| Indicator | ACCL | CVM |
|---|---|---|
| Relative Strength Index (RSI) | 45.52 | 40.69 |
| Support Level | $2.41 | $1.01 |
| Resistance Level | $3.07 | $1.79 |
| Average True Range (ATR) | 0.21 | 0.20 |
| MACD | 0.00 | -0.06 |
| Stochastic Oscillator | 54.43 | 2.28 |
Acco Group Holdings Ltd is a holding company. Through its Operating Subsidiaries, it is a multi-disciplinary, IT-driven corporate service provider with a presence in Hong Kong and Singapore. Under the Accolade brand, it specializes in offering corporate secretarial services and accounting services in Hong Kong, as well as intellectual properties (IP) registration services in Singapore. Leveraging developed IT solutions, It provides comprehensive, reliable and professional support to its clients, enabling them to focus on their core business activities while it manages and handles their corporate compliance needs. Its clientele ranges from individual clients, small and medium-sized enterprises to multinational corporations, reflecting its ability to cater to diverse business needs.
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.